Literature DB >> 31064888

Prevention, Monitoring, and Management of Cardiac Dysfunction in Patients with Metastatic Breast Cancer.

Giuseppe Curigliano1, Evandro de Azambuja2, Daniel Lenihan3, Maria Grazia Calabrò4, Daniela Cardinale5, Carlo Maria Cipolla6.   

Abstract

Cardiac monitoring is becoming an important part of breast cancer care. Breast cancer and cardiovascular disease (CVD) share many common risk factors, and it is estimated that by the median age of diagnosis, many patients with breast cancer will have established or subclinical CVD. In addition, a number of treatments for metastatic breast cancer are known to have cardiac effects. As such, there is a clear need to prevent, identify, and effectively manage cardiovascular events in patients with breast cancer. Current clinical practice for patients with metastatic breast cancer involves a comprehensive set of assessments to ensure efficacy and safety of treatment. Adding cardiac monitoring to the assessments already required for patients with breast cancer may improve survival and quality of life. Currently, cardiac monitoring is recommended for several breast cancer treatments, and guidelines related to cardiac monitoring are available. Here, we review the risk of CVD in patients with breast cancer, providing an overview of the cardiac events associated with standard therapies for metastatic breast cancer. We also assess the current clinical recommendations relating to cardiac monitoring, and practical management strategies for oncologists. Cardio-oncology is a growing medical subspecialty that promotes the need for effective cancer therapy while minimizing cardiac effects. Integrating cardiac monitoring into routine clinical practice may safeguard patients with metastatic breast cancer against adverse cardiac effects. IMPLICATIONS FOR PRACTICE: This review details the common risk factors associated with cardiovascular disease that are frequently observed in patients with metastatic breast cancer, as well as the adverse cardiac effects of many therapies that are commonly prescribed. The review also provides a rationale for routine and comprehensive cardiovascular assessment of all patients at baseline, and during and after therapy depending on the treatment and presence of risk factors for cardiovascular disease. The medical discipline of cardio-oncology is increasingly being recognized as an important part of clinical practice to ensure effective cancer therapy while maintaining cardiac health. © AlphaMed Press 2019.

Entities:  

Keywords:  Cardiac dysfunction; Cardiac monitoring; Cardio‐oncology; Metastatic breast cancer

Mesh:

Year:  2019        PMID: 31064888      PMCID: PMC6853111          DOI: 10.1634/theoncologist.2018-0773

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  79 in total

Review 1.  Telemonitoring in chronic heart failure.

Authors:  Ayesha Hasan; Vince Paul
Journal:  Eur Heart J       Date:  2011-02-02       Impact factor: 29.983

2.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Authors:  D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

Review 3.  Breast Cancer Immunotherapy: Facts and Hopes.

Authors:  Leisha A Emens
Journal:  Clin Cancer Res       Date:  2017-08-11       Impact factor: 12.531

4.  Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer.

Authors:  Keith T Flaherty; Patricia M Lorusso; Angela Demichele; Vandana G Abramson; Rachel Courtney; Sophia S Randolph; M Naveed Shaik; Keith D Wilner; Peter J O'Dwyer; Gary K Schwartz
Journal:  Clin Cancer Res       Date:  2011-11-16       Impact factor: 12.531

5.  Palbociclib and Letrozole in Advanced Breast Cancer.

Authors:  Richard S Finn; Miguel Martin; Hope S Rugo; Stephen Jones; Seock-Ah Im; Karen Gelmon; Nadia Harbeck; Oleg N Lipatov; Janice M Walshe; Stacy Moulder; Eric Gauthier; Dongrui R Lu; Sophia Randolph; Véronique Diéras; Dennis J Slamon
Journal:  N Engl J Med       Date:  2016-11-17       Impact factor: 91.245

Review 6.  Evaluation and management of patients with heart disease and cancer: cardio-oncology.

Authors:  Joerg Herrmann; Amir Lerman; Nicole P Sandhu; Hector R Villarraga; Sharon L Mulvagh; Manish Kohli
Journal:  Mayo Clin Proc       Date:  2014-09       Impact factor: 7.616

7.  Cardiovascular disease and mortality after breast cancer in postmenopausal women: Results from the Women's Health Initiative.

Authors:  Na-Jin Park; Yuefang Chang; Catherine Bender; Yvette Conley; Rowan T Chlebowski; G J van Londen; Randi Foraker; Sylvia Wassertheil-Smoller; Marcia L Stefanick; Lewis H Kuller
Journal:  PLoS One       Date:  2017-09-21       Impact factor: 3.240

8.  ANMCO/AIOM/AICO Consensus Document on clinical and management pathways of cardio-oncology: executive summary.

Authors:  Luigi Tarantini; Michele Massimo Gulizia; Andrea Di Lenarda; Nicola Maurea; Maurizio Giuseppe Abrignani; Irma Bisceglia; Daniella Bovelli; Luisa De Gennaro; Donatella Del Sindaco; Francesca Macera; Iris Parrini; Donatella Radini; Giulia Russo; Angela Beatrice Scardovi; Alessandro Inno
Journal:  Eur Heart J Suppl       Date:  2017-05-02       Impact factor: 1.803

9.  Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report.

Authors:  Cecilia Monge; Hoyoung Maeng; Alessandra Brofferio; Andrea B Apolo; Bharath Sathya; Andrew E Arai; James L Gulley; Marijo Bilusic
Journal:  J Immunother Cancer       Date:  2018-12-18       Impact factor: 13.751

10.  Timing of pubertal stages and breast cancer risk: the Breakthrough Generations Study.

Authors:  Danielle H Bodicoat; Minouk J Schoemaker; Michael E Jones; Emily McFadden; James Griffin; Alan Ashworth; Anthony J Swerdlow
Journal:  Breast Cancer Res       Date:  2014-02-04       Impact factor: 6.466

View more
  4 in total

1.  Cardiovascular Outcomes in Relation to Antihypertensive Medication Use in Women with and Without Cancer: Results from the Women's Health Initiative.

Authors:  Kerryn W Reding; Aaron K Aragaki; Richard K Cheng; Ana Barac; Sylvia Wassertheil-Smoller; Jessica Chubak; Marian C Limacher; W Gregory Hundley; Ralph D'Agostino; Mara Z Vitolins; Theodore M Brasky; Laurel A Habel; Eric J Chow; Rebecca D Jackson; Chu Chen; April Morgenroth; Wendy E Barrington; Matthew Banegas; Matthew Barnhart; Rowan T Chlebowski
Journal:  Oncologist       Date:  2020-04-06

2.  Troponins and Natriuretic Peptides in Cardio-Oncology Patients-Data From the ECoR Registry.

Authors:  Lena Hinrichs; Simone Maria Mrotzek; Raluca-Ileana Mincu; Julia Pohl; Alina Röll; Lars Michel; Amir Abbas Mahabadi; Fadi Al-Rashid; Matthias Totzeck; Tienush Rassaf
Journal:  Front Pharmacol       Date:  2020-05-19       Impact factor: 5.810

Review 3.  Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer.

Authors:  Xin-Ru Li; Xing-Han Cheng; Guo-Nan Zhang; Xiao-Xin Wang; Jian-Ming Huang
Journal:  J Ovarian Res       Date:  2022-08-16       Impact factor: 5.506

4.  Predictors of new-onset heart failure and overall survival in metastatic breast cancer patients treated with liposomal doxorubicin.

Authors:  Sebastian Szmit; Aleksandra Grela-Wojewoda; Małgorzata Talerczyk; Joanna Kufel-Grabowska; Joanna Streb; Jolanta Smok-Kalwat; Dariusz Iżycki; Ewa Chmielowska; Michał Wilk; Barbara Sosnowska-Pasiarska
Journal:  Sci Rep       Date:  2020-10-28       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.